SCM
Silverarc Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-248,728
| Closed | -$1.49M | – | 78 |
|
|
2023
Q4 | $1.49M | Sell |
248,728
-542,943
| -69% | -$3.25M | 0.44% | 52 |
|
|
2023
Q3 | $5.61M | Buy |
791,671
+30,767
| +4% | +$218K | 1.7% | 20 |
|
|
2023
Q2 | $5.36M | Buy |
760,904
+183,147
| +32% | +$1.29M | 1.66% | 17 |
|
|
2023
Q1 | $4.82M | Buy |
577,757
+305,584
| +112% | +$2.55M | 1.99% | 18 |
|
|
2022
Q4 | $3.12M | Buy |
272,173
+85,570
| +46% | +$982K | 0.89% | 35 |
|
|
2022
Q3 | $2.35M | Buy |
186,603
+133,082
| +249% | +$1.68M | 0.8% | 33 |
|
|
2022
Q2 | $566K | Sell |
53,521
-48,904
| -48% | -$517K | 0.17% | 51 |
|
|
2022
Q1 | $197 | Buy |
+102,425
| New | +$197 | 0.08% | 59 |
|
|
2021
Q1 | – | Sell |
-110,000
| Closed | -$820K | – | 90 |
|
|
2020
Q4 | $820K | Buy |
+110,000
| New | +$820K | 0.48% | 53 |
|